Literature DB >> 15133846

Expression of angiostatin cDNA in human hepatocellular carcinoma cell line SMMC-7721 and its effect on implanted carcinoma in nude mice.

Kai-Shan Tao1, Ke-Feng Dou, Xing-An Wu.   

Abstract

AIM: To transfect murine angiostatin cDNA into human hepatocellular carcinoma cell line SMMC-7721 and to investigate its effects on implanted carcinoma in nude mice.
METHODS: A eukaryotic expression vector of pcDNA3.1-mAST containing murine angiostatin was constructed. Then pcDNA3.1-mAST plasmid was transfected into cell line SMMC-7721 by Lipofectamine. The resistant clone was screened by G418 filtration and identified by RT-PCR and Western blotting. Nude mice were divided into three groups of 10 each. Mice in blank control group were only injected with SMMC-7721 cells. Mice in vector control group were injected with SMMC-7721 cells transfected with pcDNA3.1 (+) vector, whereas mice in angiostatin group were injected with SMMC-7721 cells transfected with pcDNA3.1-mAST plasmid. Volume, mass and microvessel density (MVD) of the tumors in different groups were measured and compared.
RESULTS: Murine angiostatin cDNA was successfully cloned into the eukaryotic expression vector pcDNA3.1 (+). pcDNA3.1-mAST was successfully transfected into SMMC-7721 cell line and showed stable expression in this cell line. No significant difference was observed in the growth speed of SMMC-7721 cells between groups transfected with and without angiostatin cDNA. Tumor volume, mass and MVD in the angiostatin group were significantly lower than those in the blank control group and vector control group (P<0.01). The inhibitory rate of tumor reached 78.6%. Mass and MVD of the tumors only accounted for 34.6% and 48.9% respectively of those in the blank control group.
CONCLUSION: Angiostatin cDNA could be stably expressed in human hepatocellular carcinoma cell line SMMC-7721 without obvious inhibitory effects on the growth of SMMC-7721 cells. When implanted into nude mice, SMMC-7721 cells transfected with angiostatin cDNA show a decreased tumorigenic capability. It suggests that angiostatin can inhibit tumor growth through its inhibition on angiogenesis in tumors.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15133846      PMCID: PMC4656277          DOI: 10.3748/wjg.v10.i10.1421

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  24 in total

1.  A novel strategy for the tumor angiogenesis-targeted gene therapy: generation of angiostatin from endogenous plasminogen by protease gene transfer.

Authors:  K M Matsuda; S Madoiwa; Y Hasumi; T Kanazawa; Y Saga; A Kume; H Mano; K Ozawa; M Matsuda
Journal:  Cancer Gene Ther       Date:  2000-04       Impact factor: 5.987

Review 2.  Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis.

Authors:  D Hanahan; J Folkman
Journal:  Cell       Date:  1996-08-09       Impact factor: 41.582

3.  Microvessel count predicts metastasis and prognosis in patients with gastric cancer.

Authors:  M Araya; M Terashima; A Takagane; K Abe; S Nishizuka; H Yonezawa; T Irinoda; T Nakaya; K Saito
Journal:  J Surg Oncol       Date:  1997-08       Impact factor: 3.454

4.  Angiostatin: a circulating endothelial cell inhibitor that suppresses angiogenesis and tumor growth.

Authors:  M S O'Reilly; L Holmgren; Y Shing; C Chen; R A Rosenthal; Y Cao; M Moses; W S Lane; E H Sage; J Folkman
Journal:  Cold Spring Harb Symp Quant Biol       Date:  1994

5.  Microscopic analysis and significance of vascular architectural complexity in renal cell carcinoma.

Authors:  E Sabo; A Boltenko; Y Sova; A Stein; S Kleinhaus; M B Resnick
Journal:  Clin Cancer Res       Date:  2001-03       Impact factor: 12.531

6.  Angiogenesis of liver metastases: role of sinusoidal endothelial cells.

Authors:  P Gervaz; B Scholl; C Mainguene; S Poitry; M Gillet; S Wexner
Journal:  Dis Colon Rectum       Date:  2000-07       Impact factor: 4.585

7.  Angiostatin induces mitotic cell death of proliferating endothelial cells.

Authors:  D Hari; M A Beckett; V P Sukhatme; M Dhanabal; E Nodzenski; H Lu; H J Mauceri; D W Kufe; R R Weichselbaum
Journal:  Mol Cell Biol Res Commun       Date:  2000-05

8.  Reductive surgery plus percutaneous isolated hepatic perfusion for multiple advanced hepatocellular carcinoma.

Authors:  Yonson Ku; Takeshi Iwasaki; Masahiro Tominaga; Takumi Fukumoto; Tetsuya Takahashi; Masahiro Kido; Satoshi Ogata; Masanori Takahashi; Yoshikazu Kuroda; Shinichi Matsumoto; Hidefumi Obara
Journal:  Ann Surg       Date:  2004-01       Impact factor: 12.969

9.  The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update.

Authors:  Hashem B El-Serag; Jessica A Davila; Nancy J Petersen; Katherine A McGlynn
Journal:  Ann Intern Med       Date:  2003-11-18       Impact factor: 25.391

Review 10.  Recent advances in research on multistage tumorigenesis.

Authors:  A Compagni; G Christofori
Journal:  Br J Cancer       Date:  2000-07       Impact factor: 7.640

View more
  3 in total

1.  A 176 amino acid polypeptide derived from the mumps virus HN ectodomain shows immunological and biological properties similar to the HN protein.

Authors:  Emma Herrera; Patricia Barcenas; Rubicela Hernández; Alfonso Méndez; Guillermo Pérez-Ishiwara; Blanca Barrón
Journal:  Virol J       Date:  2010-08-20       Impact factor: 4.099

2.  Proteome mapping of epidermal growth factor induced hepatocellular carcinomas identifies novel cell metabolism targets and mitogen activated protein kinase signalling events.

Authors:  Jürgen Borlak; Prashant Singh; Giuseppe Gazzana
Journal:  BMC Genomics       Date:  2015-02-25       Impact factor: 3.969

3.  Selection and Characterization of a Novel DNA Aptamer, Apt-07S Specific to Hepatocellular Carcinoma Cells.

Authors:  Xiao-Xia Yu; Ke-Li Ge; Ning Liu; Jin-Yu Zhang; Mei-Lan Xue; Yin-Lin Ge
Journal:  Drug Des Devel Ther       Date:  2020-04-20       Impact factor: 4.162

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.